The genetic test for predicting the risk of male or female hair loss in men and women becomes available in Germany under a new distribution agreement announced by pharmacogenomics research and development innovator PharmaGenoma, Inc. (PharmaGenoma) and its subsidiary HairDX, LLC. (HairDX) and Svenson Haar Studios GmbH ( Svenson), the hair solutions company in Germany.

“HairDX is a very valuable tool to determine early stages of Androgenetic Alopecia. Noninvasive treatment possibilities are greatly enhanced by early action on Androgenetic Alopecia,” says Dr. Carlos Velasco Medical Director of Svenson Group “Through HairDX, we can make the latest scientific resources available to anyone concerned with hair loss at early stages. Prevention is ever more meaningful after this test, since DNA screening analysis predicts future developments before physiological consequences occur.”

HairDX’s easy to use genetic test provides an understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

“The relationship between Svenson and HairDX expands our global footprint as an innovator in molecular dermatology. It offers the latest in genetic science to men and women in Germany,” says Andy Goren, President & CEO of HairDX, LLC.